ES2092729T3 - Benzoilguanidinas 3,4,5-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene. - Google Patents

Benzoilguanidinas 3,4,5-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.

Info

Publication number
ES2092729T3
ES2092729T3 ES93110195T ES93110195T ES2092729T3 ES 2092729 T3 ES2092729 T3 ES 2092729T3 ES 93110195 T ES93110195 T ES 93110195T ES 93110195 T ES93110195 T ES 93110195T ES 2092729 T3 ES2092729 T3 ES 2092729T3
Authority
ES
Spain
Prior art keywords
compounds
formula
medicinal product
well
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93110195T
Other languages
English (en)
Inventor
Andreas Dr Weichert
Hans-Jochen Lang
Wolfgang Dr Scholz
Udo Dr Albus
Florian Prof Dr Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2092729T3 publication Critical patent/ES2092729T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE DESCRIBEN BENZOLOGUANIDINA DE FORMULA (I) DONDE LOS COMPUESTOS DE FORMULA (I) SE OBTIENEN A TRAVES DE LA TRANSFORMACION DE COMPUESTOS DE FORMULA (II) CON GUANIDINA. R(1), R(4) SOM O R(5) R(6) N LO, ARILO Y HETARILO; R(3) R(2); R(4) Y R(5) ALQUENOILO, -CN(H2N Y R(7) CICLOALQUILO O FENILO, ASI COMO SUS SALES TOLERABLES FARMACEUTICAMENTE. LOS COMPUESTOS DE FORMULA (I), SE OBTIENEN A TRAVES DE LA TRANSFORMACION DE COMPUESTOS DE FORMULA (II) CON GUANIDINA DONDE L UN GRUPO SALIENTE SUBSTITUIBLE NUCLEOFILICAMENTE Y LIGERAMENTE. COMPUESTOS DE FORMULA (I) SON APROPIADOS COMO MEDICAMENTOS ANTIARRITMICOS CON COMPONENTE CARDIOPROTECTOR PARA PROFILAXIS Y TRATAMIENTOS DE INFARTOS ASI COMO PARA EL TRATAMIENTO DE LA ANGINA DE PECHO, COMO PREVENTIVOS EN EL PROCESO PATOFISIOLOGICO PARA REDUCIR FUERTEMENTE LOS DAÑOS INDUCIDOS ISQUEMICAMENTE DURANTE LA PRODUCCION. SE CARACTERIZA (1) A TRAVES DE LA FUERTE ACCION INHIBIDORA DE LA PROLIFERACION DE CELULAS. PUEDEN EMPLEARSE COMO ANTIARTEROESCLEROTICA, MEDIOS CONTRA COMPLICACIONES TARDIAS DIABETICAS, ENFERMEDADES DEL CANCER, ENFERMEDADES FIBROTICAS COMO FIBROSAS DEL CORAZON, DEL RIÑON O DE LOS PULMONES. SON INHIBIDORES DE ACCION COMPLETA DE LOS ANTIPORTADORES DE PROTONES SODIO CELULARES (NA+/H+ CAMBIADORES).
ES93110195T 1992-07-01 1993-06-25 Benzoilguanidinas 3,4,5-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene. Expired - Lifetime ES2092729T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4221594 1992-07-01
DE4224107 1992-07-22
DE4244319 1992-12-28

Publications (1)

Publication Number Publication Date
ES2092729T3 true ES2092729T3 (es) 1996-12-01

Family

ID=27203913

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93110195T Expired - Lifetime ES2092729T3 (es) 1992-07-01 1993-06-25 Benzoilguanidinas 3,4,5-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.

Country Status (15)

Country Link
US (1) US5693672A (es)
EP (1) EP0577024B1 (es)
JP (1) JP3490739B2 (es)
AT (1) ATE144248T1 (es)
AU (1) AU658309B2 (es)
CA (1) CA2099445A1 (es)
DE (1) DE59304166D1 (es)
DK (1) DK0577024T3 (es)
ES (1) ES2092729T3 (es)
FI (1) FI113367B (es)
GR (1) GR3021397T3 (es)
IL (1) IL106157A (es)
NO (1) NO179673C (es)
NZ (1) NZ248013A (es)
TW (1) TW328536B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4325822A1 (de) * 1993-07-31 1995-02-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
IL114670A0 (en) * 1994-08-05 1995-11-27 Fujisawa Pharmaceutical Co Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
DE4430212A1 (de) * 1994-08-28 1996-02-29 Merck Patent Gmbh Ortho-substituierte Benzoesäure-Derivate
DE4430213A1 (de) * 1994-08-28 1996-02-29 Merck Patent Gmbh Arylbenzoylguanidine
DE4430916A1 (de) * 1994-08-31 1996-03-07 Merck Patent Gmbh Alkyl-benzoylguanidin-Derivate
DE4432101A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU670224B3 (en) * 1994-09-28 1996-07-04 Chain Reaction Sales Promotion Pty Ltd Signage apparatus
TW372967B (en) * 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
DE19531138A1 (de) * 1995-08-24 1997-02-27 Merck Patent Gmbh Alkenyl-benzoylguanidin-Derivate
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
DE19622222A1 (de) * 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
JP3652708B2 (ja) 1997-03-06 2005-05-25 トーアエイヨー株式会社 シクロアルカ［ｂ］ピリジン−３−カルボニルグアニジン誘導体、その製造法およびそれを含有する医薬品
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
US6639077B2 (en) 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
AU2001261962B2 (en) 2000-05-25 2005-04-21 Merck Frosst Canada Ltd Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
EP1397359B1 (en) 2001-05-24 2005-08-31 Merck Frosst Canada & Co. 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
ATE486600T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5
WO2004050610A2 (en) * 2002-12-04 2004-06-17 Gene Logic Inc. Modulators of melanocortin receptor
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7432281B2 (en) 2003-10-07 2008-10-07 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US20080300243A1 (en) * 2005-02-28 2008-12-04 Kelly Michael G Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same
KR20070119655A (ko) * 2005-02-28 2007-12-20 레노비스, 인크. 이온-채널 리간드로서의 아미드 유도체, 및 이를 사용한제약 조성물 및 방법
SI3649109T1 (sl) * 2017-07-04 2021-11-30 Sanofi Etinilne spojine, njihova priprava in njihova terapevtska uporaba za zdravljenje malarije

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3420874A (en) * 1962-09-28 1969-01-07 Standard Oil Co Amine addition salts of nitro-carboxyalkali metal phenolates
US3247035A (en) * 1962-09-28 1966-04-19 Standard Oil Co Ammonium nitrate propellants containing a nitro-aminocarboxy-alkali metal phenolate combustion catalyst
US3780027A (en) * 1970-04-29 1973-12-18 Merck & Co Inc Anthranilic acid derivatives
US3728332A (en) * 1971-09-03 1973-04-17 Nat Starch Chem Corp Preparation of starch esters
US4178387A (en) * 1976-03-30 1979-12-11 William H. Rorer, Inc. Method for the treatment of arrhythmia
US4251545A (en) * 1979-09-19 1981-02-17 Gaf Corporation Fungicidal process using 1-(alkoxyaroyl)guanidines
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
US5093194A (en) * 1989-11-01 1992-03-03 Mobil Oil Corporation Oriented multilayer heat sealable packaging film
EP0556674B1 (de) * 1992-02-15 1996-06-19 Hoechst Aktiengesellschaft 3,5-Substituierte Benzoylguanidine, mit antiarrythmischer Wirkung und inhibierender Wirkung auf die Proliferationen von Zellen

Also Published As

Publication number Publication date
FI932998L (fi) 1994-01-02
NO932392D0 (no) 1993-06-30
JPH06116230A (ja) 1994-04-26
EP0577024B1 (de) 1996-10-16
FI932998A0 (fi) 1993-06-29
EP0577024A1 (de) 1994-01-05
DK0577024T3 (es) 1997-02-24
NZ248013A (en) 1995-12-21
NO179673C (no) 1996-11-27
CA2099445A1 (en) 1994-01-02
NO179673B (no) 1996-08-19
AU658309B2 (en) 1995-04-06
US5693672A (en) 1997-12-02
NO932392L (no) 1994-01-03
IL106157A (en) 1999-11-30
GR3021397T3 (en) 1997-01-31
DE59304166D1 (de) 1996-11-21
ATE144248T1 (de) 1996-11-15
IL106157A0 (en) 1993-10-20
JP3490739B2 (ja) 2004-01-26
AU4163593A (en) 1994-01-06
FI113367B (fi) 2004-04-15
TW328536B (en) 1998-03-21

Similar Documents

Publication Publication Date Title
ES2108144T3 (es) Benzoilguanidinas sustituidas en orto, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
GB1069343A (en) Propanolamine derivatives
MX9206305A (es) Bifenilpiridonas substitutas, procedimiento para su obtencion y medicamento que los contiene.
ES2069410T3 (es) Nuevos derivados del acido hidroxamico y n-hidroxiurea y su uso.
ES494408A0 (es) Procedimiento para la produccion de propenilaminas
AR002751A1 (es) Antifungicos de tetrahidrofurano, composiciones farmaceuticas que los contienen y el uso de los compuestos para preparar composiciones farmaceuticas utiles para el tratamiento de infecciones fungicas
ES2093945T3 (es) Composicion para el tratamiento del acne que contiene al menos un derivado de acido salicilico.
ES2055860T3 (es) Derivados 2-aminopirimidinona.
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
ES2032381T3 (es) Un compuesto quimico. (reserva del art. 167.2 cpe).
GB1459571A (en) Thiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus
ES2096840T3 (es) Benzoilguanidinas sustituidas, procedimiento para su preparacion, su uso como medicamento o agente para diagnostico, asi como medicamento que las contiene.
ES2095976T3 (es) Compuestos de pirazolopiridina y procedimiento para su preparacion.
ES2167931T3 (es) Derivados bifenilicos sustituidos por un radical aromatico o heteroaromatico y composiciones farmaceuticas y cosmeticas que los contienen.
AR002744A1 (es) Guanidinas de acido alquenilcarboxilico, sustituidas con fluorofenilo, procedimiento para su preparacion, su utilizacion como medicamento o agente dediagnostico, asi como medicamento que las contiene.
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
MX9204318A (es) Complejos de derivados de pleuromutilina para su preparacion y composiciones farmaceuticas que los contienen.
ES2019840A6 (es) Procedimiento para preparar nuevos derivados de tieno-triazolo-diazepina.
ES8400079A1 (es) Procedimiento para la preparacion de derivados de ciclohexe-no
ES2062407T3 (es) Compuestos de 2-hidroxi-3-fenoxipropilamino.
ES451188A1 (es) Un procedimiento para la preparacion de nuevas poliaminas.
ES378247A1 (es) Procedimiento para la obtencion de derivados del acido tio-carbamico.
AU530678B2 (en) Phosphono-hydroxy-acetic acid
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 577024

Country of ref document: ES